CGTX Reports Q3 Loss, Alzheimer’s Study Enrollment and Zervimesine Patent Update
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.